532 related articles for article (PubMed ID: 12499917)
1. Expression and diagnostic evaluation of the human tumor-associated antigen RCAS1 in pancreatic cancer.
Akashi T; Oimomi H; Nishiyama K; Nakashima M; Arita Y; Sumii T; Kimura T; Ito T; Nawata H; Watanabe T
Pancreas; 2003 Jan; 26(1):49-55. PubMed ID: 12499917
[TBL] [Abstract][Full Text] [Related]
2. [Evaluation of RCAS1 as serum tumor marker for pancreatic cancer].
Yang YC; Zhao YP; Liao Q; Zhang TP; Hu Y; Dai MH
Zhonghua Wai Ke Za Zhi; 2009 Jul; 47(13):999-1001. PubMed ID: 19957811
[TBL] [Abstract][Full Text] [Related]
3. High expression of tumor-associated antigen RCAS1 in pancreatic ductal adenocarcinoma is an unfavorable prognostic marker.
Hiraoka K; Hida Y; Miyamoto M; Oshikiri T; Suzuoki M; Nakakubo Y; Shinohara T; Itoh T; Shichinohe T; Kondo S; Kasahara N; Katoh H
Int J Cancer; 2002 May; 99(3):418-23. PubMed ID: 11992411
[TBL] [Abstract][Full Text] [Related]
4. Identification of Small Proteins and Peptides in the Differentiation of Patients with Intraductal Mucinous Neoplasms of the Pancreas, Chronic Pancreatitis and Pancreatic Adenocarcinoma.
Fania C; Pezzilli R; Melzi d'Eril G; Gelfi C; Barassi A
Dig Dis Sci; 2018 Apr; 63(4):920-933. PubMed ID: 29417328
[TBL] [Abstract][Full Text] [Related]
5. Significance of serum receptor-binding cancer antigen (RCAS1) in pancreatic cancer and benign pancreatobiliary diseases.
Ozkan H; Akar T; Köklü S; Coban S
Pancreatology; 2006; 6(4):268-72. PubMed ID: 16636598
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of cathepsin E in pancreatic juice in the diagnosis of pancreatic ductal adenocarcinoma.
Uno K; Azuma T; Nakajima M; Yasuda K; Hayakumo T; Mukai H; Sakai T; Kawai K
J Gastroenterol Hepatol; 2000 Nov; 15(11):1333-8. PubMed ID: 11129230
[TBL] [Abstract][Full Text] [Related]
7. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers.
Koopmann J; Buckhaults P; Brown DA; Zahurak ML; Sato N; Fukushima N; Sokoll LJ; Chan DW; Yeo CJ; Hruban RH; Breit SN; Kinzler KW; Vogelstein B; Goggins M
Clin Cancer Res; 2004 Apr; 10(7):2386-92. PubMed ID: 15073115
[TBL] [Abstract][Full Text] [Related]
8. Novel serum tumor marker, RCAS1, in pancreatic diseases.
Yamaguchi K; Enjoji M; Nakashima M; Nakamuta M; Watanabe T; Tanaka M
World J Gastroenterol; 2005 Sep; 11(33):5199-202. PubMed ID: 16127752
[TBL] [Abstract][Full Text] [Related]
9. Expression of cathepsin E in pancreas: a possible tumor marker for pancreas, a preliminary report.
Azuma T; Hirai M; Ito S; Yamamoto K; Taggart RT; Matsuba T; Yasukawa K; Uno K; Hayakumo T; Nakajima M
Int J Cancer; 1996 Aug; 67(4):492-7. PubMed ID: 8759606
[TBL] [Abstract][Full Text] [Related]
10. Differentiation of pancreatic ductal adenocarcinoma from chronic pancreatitis by PAM4 immunohistochemistry.
Shi C; Merchant N; Newsome G; Goldenberg DM; Gold DV
Arch Pathol Lab Med; 2014 Feb; 138(2):220-8. PubMed ID: 24476519
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of tumor-associated antigen RCAS1 expression in human pancreatic ductal adenocarcinoma.
Giaginis C; Davides D; Zarros A; Noussia O; Zizi-Serbetzoglou A; Kouraklis G; Theocharis S
Dig Dis Sci; 2008 Jun; 53(6):1728-34. PubMed ID: 17932753
[TBL] [Abstract][Full Text] [Related]
12. Use of immunohistochemistry for IgG4 in the distinction of autoimmune pancreatitis from peritumoral pancreatitis.
Dhall D; Suriawinata AA; Tang LH; Shia J; Klimstra DS
Hum Pathol; 2010 May; 41(5):643-52. PubMed ID: 20149413
[TBL] [Abstract][Full Text] [Related]
13. S100P is a novel marker to identify intraductal papillary mucinous neoplasms.
Nakata K; Nagai E; Ohuchida K; Hayashi A; Miyasaka Y; Aishima S; Oda Y; Mizumoto K; Tanaka M; Tsuneyoshi M
Hum Pathol; 2010 Jun; 41(6):824-31. PubMed ID: 20153506
[TBL] [Abstract][Full Text] [Related]
14. Periostin deposition in the stroma of invasive and intraductal neoplasms of the pancreas.
Fukushima N; Kikuchi Y; Nishiyama T; Kudo A; Fukayama M
Mod Pathol; 2008 Aug; 21(8):1044-53. PubMed ID: 18487994
[TBL] [Abstract][Full Text] [Related]
15. Characterization of CD24 expression in intraductal papillary mucinous neoplasms and ductal carcinoma of the pancreas.
Ikenaga N; Ohuchida K; Mizumoto K; Yu J; Kayashima T; Hayashi A; Nakata K; Tanaka M
Hum Pathol; 2010 Oct; 41(10):1466-74. PubMed ID: 20619441
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of pancreatitis-associated protein (PAP) in human pancreatic ductal adenocarcinoma.
Xie MJ; Motoo Y; Iovanna JL; Su SB; Ohtsubo K; Matsubara F; Sawabu N
Dig Dis Sci; 2003 Mar; 48(3):459-64. PubMed ID: 12757156
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of SOX9 expression in pancreatic ductal adenocarcinoma and intraductal papillary mucinous neoplasm.
Tanaka T; Kuroki T; Adachi T; Ono S; Hirabaru M; Soyama A; Kitasato A; Takatsuki M; Hayashi T; Eguchi S
Pancreas; 2013 Apr; 42(3):488-93. PubMed ID: 23146920
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic value of IMP3 and mesothelin in differentiating pancreatic ductal adenocarcinoma from chronic pancreatitis.
Ibrahim DA; Abouhashem NS
Pathol Res Pract; 2016 Apr; 212(4):288-93. PubMed ID: 26874572
[TBL] [Abstract][Full Text] [Related]
19. Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma.
Takayama R; Nakagawa H; Sawaki A; Mizuno N; Kawai H; Tajika M; Yatabe Y; Matsuo K; Uehara R; Ono K; Nakamura Y; Yamao K
J Gastroenterol; 2010; 45(1):52-9. PubMed ID: 19789838
[TBL] [Abstract][Full Text] [Related]
20. Identification of Serum Biomarker Panels for the Early Detection of Pancreatic Cancer.
Song J; Sokoll LJ; Pasay JJ; Rubin AL; Li H; Bach DM; Chan DW; Zhang Z
Cancer Epidemiol Biomarkers Prev; 2019 Jan; 28(1):174-182. PubMed ID: 30333219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
